• On March 31, GreenBox POS released the financial results for the three months (“Q4 FY 2021”) and full year (“FY2021”) ended December 31, 2021
• Company achieved record revenue in 2021 of $26.3 million, an increase of $17.8 million or 208.6% from $8.5 million in 2020
• The Q4 FY2021 results build on Q3 2021 figures in which the company reported year-over-year growth in both transaction volume and revenues
• The financial figures were accompanied by a corporate update and expected prospects for 2022.

On Thursday, March 31, at 4.30 PM Eastern, investors, stakeholders, and the general public heard about the progress that GreenBox POS (NASDAQ: GBOX), an emerging FinTech company leveraging blockchain technology to offer cutting-edge, customized payment solutions, made in the three months ended December 31, 2021 (“Q4 FY2021”) as well as throughout fiscal year 2021 (“FY2021”). GreenBox achieved record revenue in 2021 of $26.3 million, an increase of $17.8 million or 208.6% from $8.5 million in 2020. Processing volume for 2021 increased nearly tenfold to approximately $2.0 billion, from $202 million in 2020 (https://ibn.fm/zEGds). At the same time, GreenBox management hosted a conference call to discuss the financial results, offered a corporate update, and fielded questions from participants. A recording of the conference call was made available for 90 days on its website’s IR section. “Despite all GreenBox has accomplished in the last 18 months, we are still just in the early innings of our technology. We remain confident in our long-term strategy and are well positioned to capitalize on the opportunities at hand,” GreenBox CEO Fredi Nisan commented in a November 11, 2021 news release announcing the Q3 FY2021 results (https://ibn.fm/PZBgR). “2020 unquestionably proved our ability to develop and deploy cutting-edge technology. In 2021, we focused on executing on our strategy to build sustainable scale for our products, while adding new leadership team members that will drive our growth plan and establish GreenBox as a world-class brand,” said Fredi as part of the announcement of the preliminary results. “There’s a lot of pride around these 2021 results, no doubt. But, make no mistake, we remain laser-focused on molding the future of this company and our determination of becoming the global leader in the digital financial solutions marketplace,” Fredi concluded. In keeping up with the growth trajectory, GreenBox expects to process at least $4.9 billion in transactions in 2022. The company has also slated several strategic acquisitions for 2022, according to transcripts from the company’s December corporate call (https://ibn.fm/cSp1q). For more information, visit the company’s website at www.GreenBoxPOS.com. NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://ibn.fm/GBOX

• Over 31 million Americans have hearing loss but don’t utilize a hearing aid, primarily due to prohibitively high costs
• In the last 5 years, U.S. Presidents and Congress has demonstrated a strong commitment to making hearing aids affordable to all, including pressure on the FDA to complete changes now
• InnerScope has aggressively grown its business model through two key acquisitions and new sales channels that should lend to significant revenue growth as new regulations are put in place

More than 38 million Americans have some degree of hearing loss. Sadly, due mostly to prohibitively high costs, only about 20% of those people are able to improve their quality of life using hearing aids. The winds of change are blowing in for the 31 million Americans left behind, thanks to Congress prodding the U.S. Food and Drug Administration (“FDA”) to make changes and companies like InnerScope Hearing Technologies (OTC: INND) disrupting the market with new Direct-to-Consumer (“DTC”) technologies. In 2017, President Trump signed the Over-the-Counter Hearing Aid Act into law. The new law received strong bipartisan support to eliminate arcane regulations limiting availability to over-the-counter (“OTC”) hearing aids while supporting new competition in the markets to drive prices down to a level affordable by all. In July 2021, President Biden issued the Executive Order on Promoting Competition in the American Economy, which detailed his commitment to promoting OTC hearing aids for those in need. Now, it is time for the FDA to act with the comment period for key provisions in the FDA’s proposed rule for regulating OTC hearing aids ended on January 18, 2022. Congress is getting impatient with the FDA to finalize the rules to exclude any unnecessary restrictions that hinder access to OTC devices or limit their effectiveness for Americans with mild or moderate hearing loss. This point was made clear in a letter penned by Senators Chris Van Hollen (D-Md.), Elizabeth Warren (D-Mass.), and Chuck Grassley (R-Iowa) to Janet Woodcock, Acting Commissioner of the FDA, in February, which implored the agency to “finalize this rule without delay and in a manner that is consistent with congressional intent.” Changing regulations to support affordable hearing aids and competition is aligned perfectly with InnerScope expanding its business through a combination of key acquisitions and a network of major retailers and pharmacy chains. Headquartered in Roseville, California, InnerScope is a leading DTC manufacturer and distributor of FDA-registered hearing aids, hearing assistive devices, hearing health-related products, and Personal Sound Amplifier Products (“PSAPs”). Late in 2021, InnerScope moved aggressively to expand operations, buying iHear Medical and HearingAssist. The acquisition of iHear Medical brought a 40+ hearing technology patent portfolio, a research, and development team, and an R&D facility into the InnerScope family. Merging with HearingAssist was an instant revenue injection and scaling opportunity as an emerging industry powerhouse. A major hearing aid supplier to Walmart, HearingAssist generated $72 million in gross revenues in the three years before the InnerScope acquisition. These operations complement the overall InnerScope strategy to serve the millions of people that will benefit from new FDA rules. InnerScope has built out a comprehensive ecosystem, complete with an eCommerce site (www.iHearDirect.com) and a newly launched call center (www.HearingAssist.com, 1-800-700-4327), where its customers have free access to a team of highly-experienced industry talent, consisting of licensed hearing professionals, including doctors of audiology, top salespeople, and a team of hearing aid customer care representatives. The company further offers its hearing aids through partnerships with www.FSAstore.com, www.HSAstore.com, and www.WellDeservedHealth.com, online stores specializing in serving consumers enrolled in flexible spending accounts (“FSA”), health saving accounts (“HSA”), and employers’ health incentive programs. The relationship with Walmart took another positive turn with select InnerScope products making their debut in the retail giant’s online store in Canada (www.Walmart.ca). Initially, the site will feature INND’s TReO(TM) by iHEAR(R) 3-IN-1 PSAP, Hearing Assist TV Listener / Hearing Amplifier, Hearing Assist Earwax Removal Ear Spray, and Hearing Assist Dehumidifier for Hearing Aids. Hearing loss is prevalent in Canada, much like the U.S., affecting about 65% of Canadians over the age of 70. New research from Statistics Canada shows that more than half of Canadians between the ages of 40 and 79 have at least mild hearing loss, but 77% of them don’t realize it. Late in March, InnerScope announced that 9 of its products are now available on the eCommerce site of Rite Aid. The initial launch included HearingAssist’s hearing aid care and assorted hearing aid batteries, earwax removal ear spray, and a Wireless Neckband TV Listener Hearing Amplifier. Elsewhere, in recent months, InnerScope updated in-store product displays in 757 Walmart locations throughout Colorado, Tennessee, Texas, Arizona, and North Carolina; and launched 14 in-store Hearing Screening Kiosks with Hy-Vee, Giant Eagle, Food City, and Hartig Drug as part of a larger package where over 65 kiosks are already committed to retailers. Investors will be looking forward to upcoming quarterly reports to see the effect of the acquisitions, new call center, kiosks, and expanded sales channels on the top and bottom lines.  The company recently released its 2021 annual report, which showed revenues increased from $529,192 to $695,053 for fiscal 2021. Gross profits rose from $113,371 in fiscal 2020 to $490,266. With all the recent developments, InnerScope CEO and President Matthew Moore commented, “[We] have an exciting roadmap for 2022 clearly defined ahead and after the Over-the-Counter Hearing Aid Law is enacted. We continue to add new retailers to our ever-growing distribution list, including, as previously announced, Rite Aid Pharmacy. In addition, our R&D team is working to bring new proprietary patented hearing aid products to market later this year.” For more information, visit the company’s website at www.INND.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• TripAdvisor’s annual roundup of top destinations shows travelers returning to normalcy
• SHRG’s Hapi Travel Destinations focuses on offering discounted destinations with a maximized experience
• Company differentiates itself by offering unfettered access to tremendous savings, exclusive benefits on a level never before seen

Despite the global pandemic still impacting life in many ways, most indicators show that travel is picking back up. This is good news for Sharing Services Global (OTCQB: SHRG) and its new direct-selling travel division, which offers exclusive benefits and first-class discount travel opportunities. “The popular bookings website [TripAdvisor] recently published its annual roundup of top destinations, and there’s perhaps no greater sign of return to normalcy than the fact that people are once again flocking to pack beaches up and down the European coast,” reported a recent “Fast Company” article (https://ibn.fm/NUnVE). “Five of the top-10 trending destinations worldwide, which saw the largest year-over-year rise in interest on the platform, belong to the Mediterranean shoreline, including the Spanish island of Majorca, which took the top spot, as well as Rhodes and Santorini in the Aegean Sea, and Dubrovnik, Croatia, often called the ‘pearl of the Adriatic,’ and one of many countries that beckoned to digital nomads during the thick of the pandemic.” The article went on to note that within the United States, 2022’s most popular destinations included Las Vegas, which took the top spot, and New York City, New Orleans, and Nashville. Regardless of where travelers are heading, SHRG’s Hapi Travel Destinations is committed to helping them get there (https://ibn.fm/iMTNL). The company is focused on offering discounted destinations with a maximized experience and works to offer “hapi” experiences that inspire purpose and unity. The company believes that the best traveling involves sharing the joy of a global community filled with customs, cultures and experiences that enhance and enrich the lives of travelers. With its unique vision that “everyone deserves a hapi life with a bucket list of travel,” the company is committed to bringing its members world-class adventures at affordable prices. SHRG’s Hapi Travel Destinations is a travel company whose time has come. As travelers head back out in the world after a long break, they are looking for new experiences. Hapi Travel is dedicated to providing exactly that as it differentiates itself by offering unfettered access to tremendous savings and exclusive benefits to its members on a level that the industry has not seen before. Sharing Services Global Corporation is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit the company’s websites at www.SHRGInc.com, www.TheHappyCo.com, and www.HapiTravel.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Novel brain cancer drug developer CNS Pharmaceuticals is developing a proprietary pharmaceutical candidate called Berubicin for the treatment of glioblastoma multiforme (“GBM”)
• CNS has received Fast Track designation for Berubicin, which will allow the company more frequent communications with the FDA
• CNS has initiated a global potentially pivotal clinical trial to evaluate Berubicin in treating GBM and began dosing patients at sites scattered across several states last year, with numerous additional sites preparing to enroll patients in the coming months
• CNS is now reporting approval from regulatory authorities in Switzerland and France to proceed with recruiting patients there
• The study will evaluate more than 200 patients worldwide who have had a recurrence of tumor progression following standard first line therapy
• The company expects interim results from the study in 2023 after 30 to 50 percent of the total expected patients have reached the six-month point, with a primary completion date in October 2024 and ultimate resolution in February 2025

Biopharmaceutical cancer drug developer CNS Pharmaceuticals (NASDAQ: CNSP) is reporting new advances in its rollout of a global clinical trial the company describes as “potentially pivotal” in producing a treatment for an aggressive brain cancer. CNS Pharmaceuticals began recruiting and dosing patients with novel anthracycline drug candidate Berubicin in 21-day cycles last year at locations throughout the United States, and the company is continuing to prepare for recruitment at numerous other U.S. location as well as in Europe (https://ibn.fm/2azMa). Berubicin is a drug candidate for the treatment of glioblastoma (“GBM”), a brain cancer that is nearly 100 percent fatal just over a year after it’s diagnosed, on average. During the century since GBM was first identified in patients, only four drugs and one device have been approved by the U.S. Food and Drug Administration (“FDA”) to treat it, and none of the treatments have been able to significantly extend patients’ lives beyond “a few extra months,” according to the National Brain Tumor Society (https://ibn.fm/PdGXe). On April 6, CNS announced that France’s regulatory agencies have granted the company authority to pursue patient recruitment in the country, with approval for the Berubicin study coming from the National Agency for the Safety of Medicine and Health Products (“ANSM”) Competent Authority and from the People Protection Ethics Committee (“EC”) SUD-EST III (CPP Sud-Est III) (https://ibn.fm/BBy5g). France’s approval comes on the heels of similar authorization in Switzerland, where Swissmedic, the Swiss agency for therapeutic products, joined swissethics, the umbrella organization of the cantonal Ethics Committees (“ECs”), in green-lighting the clinical studies (https://ibn.fm/WfRwB). “We have said time and again that our number one priority is the advancement of this potentially pivotal study. This is evidenced by our continuous dedication to driving enrollment and bringing global clinical sites on line,” CNS CEO John Climaco stated in the most recent news release. More than 200 adult patients will participate in the “adaptive, multicenter, open-label, randomized and controlled study.” The company also hopes to establish sites in Spain and Italy, and plans to report an interim analysis of patients when 30 to 50 percent of them have reached the six-month point on study. The excitement behind Berubicin stems from its apparent ability to cross the blood-brain barrier — something unheard of in cancer-fighting anthracyclines. And an initial evaluation of Berubicin’s safety by another company 16 years ago resulted in one patient who emerged cancer-free — surviving well beyond the expected amount of time for people with GBM, and still alive and cancer free as of November 2021. Among the other 26 patients included in that initial safety test, 12 achieved some improvement or stabilization of their condition for a period of time, according to the company (https://ibn.fm/aLYwR). “The data Berubicin has shown to-date demonstrates encouraging promise in treatment of GBM. Patients and families are desperate for a viable treatment option that provides benefit and I look forward to further exploring Berubicin’s potential,” CNS’s national coordinating investigator partner in Switzerland, professor Michael Weller, MD, of the University Hospital Zurich, stated. CNS expects a primary completion date of October 2024 for the study, with final completion by February 2025 (https://ibn.fm/mhJ2b). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Lexaria Bioscience, the global innovator behind DehydraTECH drug delivery technology, has continuously focused on research into its patented technology
• The company has conducted both in vitro testing and in vivo animal and human testing to evaluate the ability of DehydraTECH to improve the delivery of various APIs (active pharmaceutical ingredients)
• Lexaria has multiple other studies lined up aimed at building sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation

As it moves toward national and international implementation and commercialization of its patented DehydraTECH(TM) drug delivery technology, Lexaria Bioscience (NASDAQ: LEXX) is aware of the need to continuously advance its understanding of the technology’s capabilities and potential applications. This informs the company’s long-held commitment to its applied research and development (“R&D”) programs, which are exclusively designed to “reduce future risks of both commercial and regulatory failure by identifying weaknesses as early as possible; and to enhance the likelihood of future commercial and regulatory success by thoroughly understanding strengths and weaknesses, also as early as possible” (https://ibn.fm/RPxts). Lexaria’s DehydraTECH technology combines a lipophilic active pharmaceutical ingredient (“API”) with a carrier particle, then it is dehydrated and finally rendered as a liquid or powder. Through the years, Lexaria has proven that DehydraTECH results in additional improvements, including speed of onset, increased brain absorption, increased bioavailability, and reduced drug administration costs, thanks to extensive research the company has continuously undertaken since 2015. So far, the research journey has involved a series of controlled and well-designed in vitro pre-clinical testing and in vivo animal and human clinical studies, as well as all-encompassing molecular characterization investigations, which have been completed on APIs such as antiviral drugs, cannabinoids, nicotine and nicotine analogs, PDE5 inhibitors and non-steroidal anti-inflammatory drugs (“NSAIDs”). The company’s in vitro pre-clinical test, an absorption study, was performed to investigate unidirectional cannabidiol (“CBD”) permeability using a human epi-intestinal tissue model with multiple formulations in the presence of simulated intestinal fluid. According to Lexaria, the study evidenced a 325% and 499%, on average, in intestinal tissue permeability compared to two control groups. Lexaria has also undertaken extensive clinical research starting in 2016. Multiple independent, well-designed, and controlled human studies conducted between 2016 and 2017, for example, corroborated the results from the in vitro studies. Since then, the company has undertaken numerous other studies evaluating the performance of various APIs processed using the DehydraTECH technology. For instance, Lexaria has investigated DehydraTECH-CBD as a potential treatment for hypertension and heart disease in multiple human studies, DehydraTECH-processed nicotine (animal study), and antivirals. “Performance of total bioabsorption (directly and indirectly through surrogate biomarkers), blood-brain-barrier delivery characteristics, rapidity of onset, consumer appeal, metabolite production (an indication of first-pass liver bypass), and quality of effectiveness have all been quantified,” Lexaria’s website says of the investigation parameters (https://ibn.fm/Ni2J1). Still, Lexaria is unrelenting in its pursuit of comprehensive datasets that would answer many questions the company expects to face from potential commercial partners or regulators and is, in fact, expanding its research. Last month, Lexaria kicked off an animal study to evaluate DehydraTECH-CBD as a potential treatment to inhibit seizure activity (https://ibn.fm/sX6tE), the first in a series of additional planned animal studies tentatively set to commence this year (https://ibn.fm/4as8P). Others include:

• HOR-A22-1: an animal study to evaluate DehydraTECH’s ability to improve the delivery characteristics of estrogen
• DEM-A22-1: an efficacy study to investigate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia
• RHEUM-A22-1: an efficacy study to evaluate the ability of DehydraTECH-CBD to potentially impact the treatment of rheumatoid disease
• DIAB-A22-1: an efficacy study to investigate DehydraTECH-CBD’s ability to potentially affect the treatment of diabetes

“DehydraTECH is not an EVOLUTION of existing technology – it is a REVOLUTIONARY new drug delivery platform. Expecting entire industries to change overnight to adopt a revolutionary process is not realistic: it takes time, evidence, and a lot of positive results to overcome industry inertia. We have long been hopeful that, before the end of 2022, we will have built sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation,” Lexaria CEO Chris Bunka wrote in a recent letter to shareholders. And with the planned and ongoing human and animal studies, Lexaria hopes to achieve precisely this. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• There is an urgent need for large-scale biosynthetic processing that preserves the purity and consistency of cannabinoids
• Acquired by InMed in October 2021, Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector
• InMed has two cannabinol formulations currently in development for ocular and dermatological diseases – INM-088 (ocular for glaucoma) and INM-755 (dermatological cream for epidermolysis bullosa)

The global cannabis market increased exponentially after the pandemic hit, and is anticipated to continue its upward trend over the next few years. The market was valued at $20.47 billion in 2020, reporting a growth rate of 50.92% that year. The sector reached $28.66 billion in 2021 and is anticipated to hit $197.74 billion in 2028, expanding at a CAGR of 32.04% (https://ibn.fm/2o10w). The market growth is paired with an increased demand for rare cannabinoids, with research showing that the biosynthesis of rare cannabinoids is projected to reach $25 billion in 2025 and up to $40 billion by 2040 (https://ibn.fm/jBXUs). The problem faced by companies looking to work with rare cannabinoids on an industrial scale is the lack of efficient biosynthetic production methods that can ensure purity and consistency at high levels of production. Many companies find small-scale processing efficient for maintaining purity and consistency, but InMed Pharmaceuticals (NASDAQ: INM), which sees the potential of rare cannabinoids, is looking to scale up their production to commercial levels, and advanced biosynthetic production methods are necessary to ensure purity and consistency at such levels. InMed is a clinical-stage company that is currently developing a pipeline of cannabinoid-based pharmaceutical drug candidates to treat several diseases with high, unmet medical needs. The company’s focus is on rare cannabinoids, many of which have variants that are not yet available in commercial-size quantities, such as cannabidivarin – CBDV and tetrahydrocannabivarin – THCV. The acquisition of Bay Medica in October 2021 has provided an advantage for InMed in the rare cannabinoid biosynthesis industry. Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector and now operates as a subsidiary of InMed. Bay Medica is comprised of a team of key scientists and professionals from large-scale producers, which gives InMed the unique opportunity to use the technology to scale up the rare cannabinoid synthesis production. In a January news release, Shane Johnson, SVP and General Manager of Bay Medica, said the company was delivering on its objective to launch additional rare cannabinoids in early 2022 in response to inbound demand. “By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large-scale supplier of high-quality rare cannabinoids in these sectors,” Johnson explained. Evidence suggests that rare cannabinoids may produce exceptional therapeutic value. One of the rare cannabinoids that InMed has been working with is cannabinol (“CBN”). CBN is the active pharmaceutical ingredient (“API”) in two lead programs being pursued by the company for ocular and dermatological diseases. The company’s most advanced compound currently pursued is INM-755, a CBN topical cream under clinical development for treating epidermolysis bullosa (“EB”), a severe genetic skin disorder. InMed is also developing INM-088, an ocular CBN formulation researched for glaucoma treatment. INM-755 commenced a Phase 2 EB study across 13 sites in eight European countries in 2021. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders
• It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolio
• For 2022, the company plans to build on the progress achieved in 2021
• With new additions to its board, its conditional IRB approval, and the clinical research it has lined up for the new year, Mydecine is confident that it will meet its anticipated capital markets initiatives for 2022

Founded in 2020, Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) has pushed the envelope, particularly in innovating both first- and second-generation novel therapeutics for the treatment of unmet needs in mental health and addiction disorders. Over the past couple of years, it has pursued indications including, but not limited to Post-Traumatic Stress Disorder (“PTSD”), addiction and anxiety, and has made significant progress while at it. In 2021 the company made significant strides toward creating and commercializing new treatments for mental health and addiction disorders, and received conditional IRB approval to advance its Phase 2b smoking cessation study, which the company is confident will yield FDA Investigational New Drug (“IND”) approval in Q2 2022 (https://ibn.fm/sv7UB). More importantly, the year marked a significant shift for the company, focusing on reducing its expenses and increasing efficiencies in a bid to continue progressing its clinical trials and expanding its intellectual property (“IP”) portfolio. As of December 31, 2021, Mydecine had $1.5 million in cash and cash equivalents. Additionally, the company secured additional funding for its clinical trials and its IP portfolio expansion projects. Going forward, Mydecine plans to focus on clinical research, particularly Phase 2b of its smoking cessation clinical study, along with drug development, mainly highlighted by its Artificial Intelligence (“AI”) drug discovery program. “Over the last year, our new chemical entity (“NCE”) program has produced multiple patents covering several second-generation novel molecules that we believe will offer significant improvements over classic psilocybin and MDMA,” noted Rob Roscow, the Chief Scientific Officer at Mydecine. “We’re using a modular development approach to our patent strategy, which gives us the flexibility to license, partner or develop our lead drug candidates from our multiple families of NCEs, all wholly owned by Mydecine,” he added. In 2021, the company filed several provisional and full patent applications for novel molecules with the potential to outperform first-generation compounds safely. These applications covered novel MDMA analogs, improved psilocybin, other tryptamines, and potential heart-safe micro-dosing drugs, among others. Its management is confident that these patents will aid in taking the company to the next level in terms of performance and creating value for its shareholders. Mydecine also announced new independent board member appointments, including Gordon Neal, Josephine Wu, Dr. Saeid Babaei, and Dr. Victoria Hale. They bring a wealth of experience in drug development, clinical trials, and technology, and will be integral to the company meeting its anticipated capital markets initiatives for 2022. Mydecine is optimistic about the new year. With great things lined up, from clinical trials to new drug developments, the company is confident that it will help push the industry forward and create incredible value for its shareholders. “I’d like to personally thank our shareholders, board members, and highly dedicated team for enabling Mydecine to reach these significant milestones, and we look forward to another successful year,” noted Josh Bartch, Mydecine’s Chief Executive Officer (“CEO”). For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• The company exhibited at the premier event, held March 31–April 1, 2022
• ACT has worked to strengthen its presence in the cannabis space
• This strategic positioning comes as the global cannabis packaging market is projected to reach $297.51 billion by 2026

Advanced Container Technologies (OTC: ACTX) recently wrapped up a successful appearance at the CannaCon Conference, showcasing its new product line and strengthening brand awareness. The company exhibited at the premier event, held March 31–April 1, 2022, alongside Grassfire Distro, ACT’s exclusive packaging reseller (https://ibn.fm/WqmI3). Prior to the two-day event, Advanced Container Technologies CEO Doug Heldoorn noted that ACT had experienced “tremendous success” at last year’s CannaCon Conference. “We have an extensive line of new and exciting products that can help cannabis companies maximize profits throughout the ecosystem — from the cultivator to the retailer,” he stated. Since its participation in CannaCon last year, Advanced Container Technologies has worked to strengthen its presence in the cannabis space. Recognizing that safe, quality packaging in the sector is essential, ACT offers an impressive line of products, including an array of options for virtually every type of cannabis and hemp product, branding solutions, controlled environment cultivation systems, lighting, nutrients and a variety of other essential items. Most recently, the company launched its Store ‘n Seal bags, a new line of premium-quality packaging (https://ibn.fm/O4KVM). The new commercial-grade bags are leak proof, odor proof and watertight, and are designed to store vegetables, lettuce, leafy greens and even cannabis safely. The bags, which feature thick 5ml plastic with a resealable zipper across the top, are available in two varieties: a silver bag with a see-through window and a black-out bag. Each bag holds up to two pounds of product. This strategic positioning comes as the global cannabis packaging market is projected to reach $297.51 billion by 2026, with a CAGR of 22.59% (https://ibn.fm/yf57Z). ACT’s quality options aren’t going unnoticed; the company recently reported year-over-year revenues that show a 209% increase over the prior period, and company management expects that trend to continue. “We believe that we are in a stronger position than most of our competitors who are hampered by enormous operating expenses and dwindling growth rates,” says Heldoorn. “With our focus on remaining nimble and keeping costs and operating expenses as low as possible, we are in an excellent position to continue to grow rapidly outperform our competition in many key indicators.” “As the cannabis market continues to become more competitive, it becomes even more important for companies to find new ways to increase profitability,” Heldoorn added. “Our unique product line can help companies grow brands, deepen customer loyalty, and increase profits.” Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented, proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com. NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://ibn.fm/ACTX

 

• NEI reports strong bipartisan support for nuclear energy throughout the 117th Congress
• Hallmark pieces of legislation have demonstrated that carbon-free, always-on nuclear power is an indispensable driver of our clean energy future
• Institute notes that more can be done “to ensure gigawatts of electricity remain on the grid and new reactors are deployed”

Clean energy has become a top priority worldwide, and the U.S. is no exception. House representatives and senators in the nation’s capital have spent plenty of time talking about and voting on energy, including nuclear energy, and many companies, including Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), are paying attention to what’s happening in Washington, DC. “There has been strong bipartisan support for nuclear energy throughout the 117th Congress,” reported the Nuclear Energy Institute (“NEI”), the policy organization of the nuclear technologies industry, in a recent blog (https://ibn.fm/evlYU). “Decarbonization efforts and the clean-energy transition have received heightened attention on the Hill, and hallmark pieces of legislation have demonstrated that carbon-free, always-on nuclear power is an indispensable driver of our clean energy future. “In November, Congress passed the bipartisan $1.2 trillion infrastructure package, which featured major investments in nuclear energy,” the article continued. “The bill contained continued funding for the Advanced Reactor Demonstration Program (‘ARDP’), a demonstration program for Regional Clean Hydrogen Hubs, and support for operating nuclear plants at risk of closure.” The blog mentioned the Build Back Better Act, which is currently on the back burner but contains “broadly supported climate provisions [that] include a production tax credit (‘PTC’) for electricity generated by nuclear power plants in operation today, as well as tax credits for all clean electricity technologies, including advanced nuclear and power uprates that begin construction after 2026,” the piece continued. “The bill also includes funding for the development of a domestic high-assay low-enriched uranium (‘HALEU’) supply, a fuel which is essential to the demonstration of advanced reactors, as well as resources to support efforts such as the coal to nuclear transition.” The NEI piece also noted that the importance of nuclear was being acknowledged in other pieces of critical legislation, including the National Defense Authorization Act (“NDAA”), which was passed in December and “recognized the role advanced nuclear will play in both our national security and climate goals. The Department of Defense will work to deploy microreactors, helping to advance these technologies into commercialization so that they can provide clean energy to remote areas.” In addition, the blog called out several smaller, nuclear-specific bills introduced during this Congress. “These sustained, bipartisan efforts to advance nuclear energy signal a push to meet our climate goals, while also providing jobs and stimulating local economies with new nuclear,” the blog stated. Those bills included the American Nuclear Infrastructure Act (“ANIA”); the Advanced Nuclear Deployment Act; the Nuclear Licensing Efficiency Act; the Modernize Nuclear Reactor Environmental Reviews Act; and the Accelerating Nuclear Innovation through Fee Reform Act; the Fission for the Future Act; the Strengthening American Nuclear Competitiveness Act; and an historic budget request for nuclear from the administration in 2021. “While a bipartisan coalition has boldly committed to supporting new nuclear and protecting operating plants, there is more to be done to ensure gigawatts of electricity remain on the grid and new reactors are deployed,” the blog concluded. “Incentivization programs that value carbon-free energy and fund the next generation of climate technologies, such as advanced nuclear, are essential to meeting our climate goals.” A member of the NEI, Energy Fuels is keenly interested in what happens on a federal level. The company operates three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch ISR Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of more than 8 million pounds of U₃O₈ per year. The mill is also currently in commercial production of the most advanced rare earth element material being produced in the U.S. today. The mill also produces vanadium when market conditions warrant. The Nichols Ranch ISR Project is currently on standby and has a licensed capacity of 2 million pounds of U₃O₈ per year. The Alta Mesa ISR Project is also currently on standby. In addition to these production facilities, Energy Fuels has one of the largest NI 43-101-compliant uranium resource portfolios in the country, along with several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• The security robot market was valued at $8.87 billion in 2020 and is expected to grow to $19.77 billion by 2026
• Knightscope’s autonomous security robots bridge the gap between unmet security needs and the security demands of a rising population
• The committed equity facility provides Knightscope with the right to sell and issue up to $100 million of its Class A Common Stock

Since the pandemic, an increased need for autonomous technology in the private security and asset protection industries has become apparent, resulting in a growing market for these solutions. The most recent census reported 325 million people living in the United States, but there are only approximately 700,000 local, state, and federal police officers to protect the population – an industry shortage that can be compensated through the implementation of security robots, like the K5 by Knightscope (NASDAQ: KSCP). As technological developments in the industry evolve, security robots are benefited from improved automation and sensor technology capabilities. Development and improvement in neural network technology have given robots the ability to learn over time – improving overall functionality. As a result, the security robot market is constantly expanding, from $8.87 billion in 2020 to an anticipated value of $19.77 billion by 2026, registering a CAGR of close to 14% during the forecast period of 2021-2026 (https://ibn.fm/g3p7F). Knightscope is a Silicon Valley-based company specializing in advanced security technologies and constructing autonomous security robots (“ASRs”) that deter, detect, and report. Knightscope recently met the security needs of a Silicon Valley commercial real estate (“CRE”) twin-tower office complex, deploying its K5 ASR to answer the property manager’s need for a security strategy for the building’s stakeholders (https://ibn.fm/iYWwV). Knightscope’s K5 ASR is a fully autonomous outdoor security robot with over one million hours of logged, commercially operated service with the ability to run 24/7. With indoor and outdoor terrain capabilities, the K5 has a maximum speed of 3 mph, weighs 398 pounds, and measures 36” (L) x 33.5” (W) x 62.5” (H). Integrated with the Knightscope Security Operations Center (“KSOC”), a browser-based user interface, human eyes can use the real-time data for autonomous detection, including:

• Force Multiplying Physical Deterrence
• Eye-Level 360-Degree HD Video Streaming and Recording
• People Detection During Certain Restricted Hours
• Thermal Anomaly Detection
• Automatic Signal Detection
• License Plate Recognition

The K5 is also weatherproof, allowing outdoors operation, even in adverse conditions. The ASR was also created with ramp accessibility in mind. Knightscope is also making it possible for clients to meet their line of ASRs – through the Robot Roadshow. Clients can either visit virtually or schedule a pod visit on the company’s website. Knightscope recently marked its 9th anniversary (April 4) and announced on the occasion that it had entered into a $100 million common stock purchase agreement with B. Riley Principal Capital. The committed equity facility provides Knightscope with the right (without obligation) to sell and issue up to $100 million of its Class A Common Stock over a period of 24 months to B. Riley at its own discretion – more details can be found in the Form 8-K to be filed by Knightscope with the SEC. “I believe about 95% of startups fail, and the odds of starting a company, growing it, and taking it public are likely in the winning-the-lottery type of odds… but we stuck together and did it with the help of all of our partners! Congratulations and many thanks to the entire Knightscope team, our clients, investors, and suppliers,” Knightscope’s chairman and CEO William Santana Li said, commenting on the 9-year milestone for the company (https://ibn.fm/2TJXi). For more information about Knightscope, visit the company’s website at www.Knightscope.com, and if you are considering subscription service you can request a private demonstration of the technology at www.Knightscope.com/demo. NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP